Why Moderna Might Make Less Money This Year Than Everyone Expects
Moderna (NASDAQ: MRNA) hit a home run with its first-quarter results. The company's Q1 revenue of $6.1 billion blew past the Wall Street estimate of $4.6 billion. It posted earnings per share of $8.58 -- trouncing the consensus view of $5.21 per share.
It looks like 2022 is shaping up to be an even stronger year for Moderna than 2021. The company reaffirmed its full-year revenue guidance of $21 billion. Analysts think the actual total could be higher, with an average estimate of a little over $22 billion.
But those numbers could prove to be overly optimistic. Here's why Moderna might make less money this year than everyone expects.
Source Fool.com
